Please confirm topic selection

Are you sure you want to trigger topic in your Anconeus AI algorithm?

Please confirm action

You are done for today with this topic.

Would you like to start learning session with this topic items scheduled for future?

Updated: Apr 24 2026

Blood Loss Management in Spine Surgery

Images
https://upload.orthobullets.com/topic/422819/images/cox_diagram.jpg
https://upload.orthobullets.com/topic/422819/images/partial-thromboplastin-time.jpg
  • PREOPERATIVE
    • Establish baseline laboratory studies
      • CBC
        • hemoglobin & hematocrit
        • platelets
      • prothrombin time (PT)
        • not correlated with increased transfusion rates
      • partial thromboplastin time (PTT)
        • assesses clotting time of the intrinsic clotting cascade
        • factors XII, XI, IX, VIII, X, V, and II
        • normal 25-39 seconds
        • not correlated with increased transfusion rates
      • fibrinogen
        • also known as factor I
        • normal 200-400 mg/dL
        • below normal ranges have been associated with increased transfusion rates
    • Preoperative blood loss estimation
      • allows for cost-effective treatment with cell salvage systems, allogenic blood transfusions, and antifibrinolytic agents
      • factors associated with increased blood loss:
        • increased body mass index
        • advanced age
        • bleeding diathesis
        • use of instrumentation
        • revision spine surgery
        • iliac crest bone graft harvest
        • interbody fusions
        • trauma or tumor surgery
        • Cobb angle >50°
        • longer expected surgical time
        • neuromuscular scoliosis
        • >6 levels fused for deformity surgery
        • Ponte osteotomies
      • recommend obtaining a preoperative hemoglobin level of 5 g/dL greater than the treating surgeon's transfusion trigger
      • Anticoagulation Medications
      • Drug
      • Plasma Half-Life (Hours)
      • Effect on Bleeding
      • Minimum Cessation Prior to Surgery (Days)
      • Diclofenac
      • 1-2
      • Inhibits COX (reversibly)
      • 1
      • Ibuprofen
      • 2
      • Inhibits COX (reversibly)
      • 1
      • Indomethacin
      • 4-10
      • Inhibits COX (reversibly)
      • 3
      • Ketorolac
      • 5-7
      • Inhibits COX (reversibly)
      • 3
      • Etodolac
      • 6-7
      • Inhibits COX (reversibly)
      • 3
      • Sulindac
      • 8-16
      • Inhibits COX (reversibly)
      • 3
      • Naproxen
      • 12-17
      • Inhibits COX (reversibly)
      • 3
      • Piroxicam
      • 50
      • Inhibits COX (reversibly)
      • 7
      • Celecoxib
      • 11
      • Inhibits COX-2 (reversibly)
      • 1
      • Aspirin
      • 6
      • Inhibits COX (irreversibly)
      • 7
      • Clopidogrel
      • 1
      • Irreversibly inhibits platelet ADP receptors
      • 7
      • Prasugrel
      • 2-15
      • Irreversibly inhibits platelet ADP receptors
      • 7
      • Ticagrelor
      • 7-9
      • Reversibly inhibits platelet ADP receptors
      • 5
      • Ticlopidine
      • 20-50
      • Irreversibly inhibits platelet ADP receptors
      • 14
      • Warfarin
      • 20-60
      • Inhibits vitamin K-dependent clotting factor synthesis
      • 5
      • Enoxaparin (LMWH)
      • 3-5
      • Binds antithrombin and irreversibly blocks thrombin
      • 1
      • Unfractionated heparin
      • 0.5-2
      • Binds antithrombin and irreversibly blocks thrombin
      • 4-5 hours
      • Dabigatran
      • 7-14
      • Reversibly blocks thrombin
      • 3
      • Rivaroxaban
      • 5-13
      • Reversibly blocks factor Xa
      • 3
      • Apixaban
      • 9-14
      • Reversibly blocks factor Xa
      • 3
      • Edoxaban
      • 10-14
      • Reversibly blocks factor Xa
      • 3
  • Intraoperative Management
    • Hypotensive anesthesia
      • administration of vasodilating agents to a goal systolic blood pressure of 50-80 mm Hg or MAP of 60 mm Hg
        • well validated in pediatric scoliosis surgery
        • has been shown to decrease intraoperative blood loss by 55% without sequelae
        • reduces blood extravasation through the surgical wound
        • does not affect bone bleeding (mostly venous bleeding)
    • Maintenance of normothermia
      • ideal to keep body temperature >36°C
        • decrease in body temperature >1°C can increase blood loss by 16% and increase transfusion rates by 22%
        • hypothermia decreases platelet function and coagulation enzyme activity
      • increase OR temperature if needed
      • minimize exposed skin surface area until draping
    • Patient positioning
      • reverse Trendelenburg positioning
        • decrease central venous pressure
      • Jackson frames that allow abdomen to hang freely
    • Tranexamic acid (TXA)
      • lysine derivative that competitively blocks plasmin binding sites on fibrin
        • results in a decrease in fibrinolysis and stabilized clot formation
        • 6 to 10 times more potent than epsilon aminocaproic acid
      • multiple studies have demonstrated a significant reduction in operative blood loss and transfusion rates with perioperative administration
        • no increased risk of DVT and PE
        • does not alter PT and PTT times
      • multiple dosing regimens and routes of administration utilized
        • IV, oral, and topical all appear equally efficacious
      • contraindications:
        • history of CVA
        • allergy
        • severe CAD
    • Desmopressin
      • vasopressin analog
        • increases factor VIII and von Willebrand factor
      • limited data in spine surgery
      • useful for treating patients with von Willebrand disease
    • Aminocaproic acid
      • lysine derivative that competitively inhibits plasmin
        • results in decreased fibrinolysis
      • studies have demonstrated decreased blood loss with aminocaproic acid in arthroplasty
      • lower cost than TXA
      • does not decrease seizure threshold
    • Topical hemostatic agents
      • collagen agents
        • stimulate the intrinsic pathway of coagulation cascade to promote hemostasis
      • fibrin sealant
        • combining the mixtures creates a fibrin seal where it is sprayed
      • platelet-rich plasma
        • centrifugation of the patient's blood to isolate plasma with high contents of platelets, growth factors, and clotting factors
        • proposed benefit of improved hemostasis, wound healing, and recovery
      • platelet-poor plasma
        • isolated from centrifugation process
        • combined with thrombin and calcium to provide an autologous fibrin sealant
      • Gelfoam sponges
        • manufactured from animal-skin gelatin and processed into sponge-form
        • isolated use exerts mostly mechanical hemostasis against low-pressure bleeders
        • can be soaked with thrombin, which can act as scaffold for the coagulation cascade
        • excess Gelfoam should be removed as it may interfere with bone healing
      • topical hemostatic agents do not appear to be cost-effective in total joint arthroplasty cases
        • beneficial in spine surgery to promote hemostasis without inflicting harm to adjacent neural structures
      • topical TXA
        • typically administered near the end of the procedure to control postoperative bleeding
        • decreases fibrinolysis and stabilizes clot formation
        • )may be an alternative route of administration in patients with higher risk of complications (history of MI, CAD, or CVA)
      • gelatin-thrombin matrix
        • consists of porcine or bovine gelatine matrix combined with human derived thrombin
        • acts of the end stage of the coagulation cascade  fibrin formation
    • Reinfusion systems (Cell Saver)
      • recycles intraoperative blood loss for later transfusion
        • can be transfused intraoperatively during longer procedure
      • suctioned blood is filtered, washed, and transfused within 6 to 8 hours of the procedure
        • serves as an alternative to allogenic blood transfusion
        • theoretical benefits of minimizing wound complications and hematoma formation
        • need to avoid suctioning antibiotic irrigation, povidone-iodine solution, and irrigation >42°C into the circuit
      • indications:
        • religious beliefs that preclude allogenic blood transfusion
        • large number of autoantibodies that makes allogenic blood stock incompatible
      • contraindications:
        • surgeries for malignancy and infection
      • not recommended for routine use in lumbar spine surgery
        • not cost effective unless blood loss ≥500 cc
  • Postoperative Management
    • Allogenic blood transfusion
      • preoperative hemoglobin is the strongest risk factor for postoperative blood transfusion
        • <13 g/dL more likely to require
      • other risk factors
        • female gender
        • increased age
        • larger patient size
        • longer procedures
        • lateral releases in total knee arthroplasty
      • 1 unit increases Hb by 1 g/dL
      • no absolute criteria for transfusion
        • transfusion should be considered for anyone with Hb <6 g/dL
        • transfusion should be considered for postoperative patients with Hb 7-8 g/dL
    • Postoperative iron supplementation
      • daily oral iron replacement for mild acute blood loss anemia
    • Drains
      • theoretically prevents surgical site hematomas
        • potential site for infection or neural compression
      • concern for increased post-operative blood
        • negates the tamponade effect by decreasing intra-wound pressure
  • Special Considerations
    • Jehovah's Witness (JW)
      • hold beliefs that blood transfusions are forbidden by the bible
        • some patients may still consent to a blood transfusion
        • some patients may consider the use of Cell Saver as an alternative to allogenic blood transfusion
      • use of colloids and coagulation factors are not forbidden and a matter of personal choice
      • bovine-derived hemostatic agents are generally approved by JW
flashcard locked
Create a free account or log in to see the cards.
Private Note